AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts

Amarin's future with fish oil-derivative Vascepa looks rocky after the drugmaker's Hail Mary appeals to protect its flagship drug's patents fell flat. But even with its future uncertain, subanalyses from Vascepa's pivotal outcomes trial continue to trickle in and build the drug's case with doctors.